The AML Sessions: Venetoclax-based regimens

The BCL-2 inhibitor venetoclax has been evaluated in many hematological malignancies, including acute myeloid leukemia (AML). More recently, emerging mechanisms of resistance and future directions of venetoclax in combination with hypomethylating agents and IDH inhibitors have been evaluated and data presented at EHA 2020, as well as SOHO 2020 has shown promising results in AML.

In this podcast, Naval Daver, of The University of Texas MD Anderson Cancer Center, Houston, TX, leads an exciting discussion alongside Courtney DiNardo and Marina Konopleva, also from The University of Texas MD Anderson Cancer Center, as well as Andrew Wei of Monash University, Melbourne, Australia, on the latest updates in the use of venetoclax-based regimens for the treatment of AML.

The post The AML Sessions: Venetoclax-based regimens appeared first on VJHemOnc.